Pacira BioSciences, Inc. Presents Real-World Data On EXPAREL Showing Lower Total Healthcare Costs In Outpatient Total Hip And Knee Arthroplasty Procedures

Published: 2026-04-13 15:08:09 ET PCRX

Published on 04/13/2026 at 03:08 pm EDT

Pacira BioSciences, Inc. presented data from three real-world studies supporting the economic value of EXPAREL (bupivacaine liposome injectable suspension) in total hip arthroplasty (THA) and total knee arthroplasty (TKA) procedures performed in hospital outpatient department (HOPD) settings at the Academy of Managed Care Pharmacy (AMCP) Annual 2026 Meeting, taking place April 13-16 in Nashville, Tennessee. Across the analyses, EXPAREL use was associated with lower or comparable total healthcare costs and reduced opioid utilization in certain patient populations over follow-up periods of up to six months.Select findings include: In one study, the use of EXPAREL for Total Hip Arthroplasty (THA) in hospital outpatient departments (HOPDs) was associated with lower total healthcare costs over 3 and 6 months of post-surgical follow-up. More pronounced cost savings for patients with lower back pain as well as reduced opioid usage compared to patients who did not receive liposomal bupivacaine (non-LB) were also observed.

In the second assessment, EXPAREL use during HOPD Total Knee Arthroplasty (TKA) was associated with comparable or lower healthcare costs, particularly in teaching hospitals. The third assessment was a three-year budget impact analysis, that found that EXPAREL use was associated with a projected cumulative absolute cost difference of -$117,868 per 1 million members by year 3 compared to ropivacaine in the HOPD Commercial and Medicare Advantage settings, with higher pharmacy acquisition costs offset by reductions in total healthcare expenditures.